(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 November 2008 (06.11.2008)

PCT

(10) International Publication Number
WO 2008/132494 A1

(51) International Patent Classification:
C07K 14/47 (2006.01)

(21) International Application Number:
PCT/GB2008/001548

(22) International Filing Date: 1 May 2008 (01.05.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/924,145 1 May 2007 (01.05.2007) US

(71) Applicants *(for all designated States except US)*: **LUDWIG INSTITUTE OF CANCER RESEARCH** [US/US]; 605 Third Avenue, New York, NY 10158 (US). **UCL BUSINESS PLC** [GB/GB]; The Network Building, 97 Tottenham Court Road, London W1T 4TP (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NEMAZANYY, Ivan** [UA/GB]; Research Department of Structural and MolecularBiology, University College London, Gower Street, London WC1E 6BT (GB). **PANASYUK, Gana** [UA/GB]; Research Department of Structural and MolecularBiology, University College London, Gower Street, London WC1E 6BT (GB). **ZHYVOLOUP, Alexander** [GB/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB). **WATERFIELD, Michael** [GB/GB]; Emeritus Courtauld Professor of Biochemistry, University College London, Gower Street, London WC1E 6BT (GB). **GOUT, Ivan** [UA/GB]; Research Department of Structural and MolecularBiology, University College London, Gower Street, London WC1E 6BT (GB).

(74) Agents: **KEEN, Celia** et al.; J.A. KEMP & CO., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(54) **Title:** TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (MTOR) PROTEIN

(57) **Abstract:** The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.

WO 2008/132494 A1